XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Operating activities    
Consolidated net loss $ (142,377) $ (24,766)
Less: Loss from discontinued operations, net of tax (1,830) (1,705)
Loss from continuing operations (140,547) (23,061)
Adjustments to reconcile consolidated net loss to net cash used in operating activities    
Depreciation and amortization 72 70
Deferred income taxes 6
Net unrealized loss (gain) on investments - Hedge Funds 504 (4,758)
Realized loss on available-for-sale securities 45
Impairment of investments - Other Pharmaceuticals 724
Impairment of cost method investment - Cornerstone Pharmaceuticals 79,141
Impairment – Altira 7,000
Provision for loss on receivable from Cornerstone Pharmaceuticals pursuant to line of credit 25,000
Equity in loss (earnings) of RP Finance 575 (383)
Provision for losses on related party receivables 10,095
Provision for doubtful accounts 4 193
Stock-based compensation (credit) expense (917) 6,633
Gain on sale of building (749)
Change in assets and liabilities, net of effects from discontinued operations:    
Interest receivable (140)  
Trade accounts receivable 74 (161)
Prepaid expenses and other current assets (3,545) (802)
Other assets 130 63
Accounts payable and accrued expenses 52 164
Other current liabilities 3,566 137
Due to related parties (67) 136
Due from related parties (482)
Due from Cornerstone Pharmaceuticals (120)
Other liabilities 40 (44)
Net cash used in continuing operations (26,038) (15,314)
Net cash used in discontinued operations (41) (287)
Net cash used in operating activities (26,079) (15,601)
Investing activities    
(Purchases) dispositions of property and equipment (2) 44
Payment to fund RP Finance Line of Credit (1,875) (7,500)
Payment to Cornerstone Pharmaceuticals pursuant to Line of Credit (25,000)
Purchases of available-for-sale securities (65,306)  
Proceeds from maturities of available-for-sale securities 28,500  
Proceeds from sale of building   3,658
Proceeds from sale of Hedge Funds 7,000
Purchase of Investment in Altira (2,000)
Investment in Rafael Pharmaceuticals (9,123)
Net cash used in investing activities of continuing operations (63,683) (7,921)
Net cash used in investing activities of discontinued operations (113) (250)
Net cash used in investing activities (63,796) (8,171)
Financing activities    
Contribution from noncontrolling interest of consolidated entity 912
Proceeds from exercise of options 71
Proceeds from exercise of warrants 2,000
Proceeds from issuance of common stock 99,170 13,000
Proceeds from issuance of common stock from related party 10,997
Payment of transaction costs incurred in connection with sale of common stock (6,228)
Payments for taxes related to shares withheld for employee taxes (75) (185)
Net cash provided by financing activities of continuing operations 103,864 15,798
Net cash provided by financing activities of discontinued operations 14,500
Net cash provided by financing activities 103,864 30,298
Effect of exchange rate changes on cash and cash equivalents (306) 122
Net increase in cash and cash equivalents and restricted cash 13,683 6,648
Cash and cash equivalents, and restricted cash, beginning of year 12,854 6,206
Cash and cash equivalents, and restricted cash, end of year 26,537 12,854
Supplemental schedule of noncash investing and financing activities    
Common shares issued for payment of purchase price for Altira equity 8,501
Acquisition of additional ownership interest in LipoMedix 8
Reconciliation of cash and restricted cash    
Cash and cash equivalents 26,537 7,854
Restricted cash 5,000
Total cash and cash equivalents and restricted cash shown in statement of cash flows $ 26,537 $ 12,854